Tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof

Abstract

The invention relates to a tumor binding specific gamma delta TCR gene modified alpha beta T cell and cancer suppression application thereof. The alpha beta T cell expresses the tumor binding specific gamma delta TCR; the tumor binding specific gamma delta TCR comprises a gamma 4 chain and a delta 1 chain; the amino acid sequence of the delta 1 chain CDR3 is shown as SEQ ID NO: 1. Experiment results prove that the cell has cytotoxicity for a plurality of tumor cells, and a novel method and a novel strategy are provided for adoptive immunotherapy of tumors.

Description

technical field

[0001] The invention relates to the field of gene-modified lymphocyte adoptive immunotherapy. In particular, it relates to a tumor-binding specific γδTCR gene-modified αβT cell and its tumor-suppressing application. Background technique

[0002] Immunotherapy of tumors is highly expected by people. Its principle is to artificially regulate the immune function status of tumor patients and regulate the balance between various links of anti-tumor immunity through the use of modern biotechnology, so as to control tumors or reduce the risk of treatment. The purpose of related toxic side effects. Among all the currently developed immunotherapeutic approaches, the adoptive immunotherapy of cells, through in vitro activation and expansion of autologous or allogeneic immune effector cells and then infused into patients, is considered to be the most potential immunotherapy strategy.

[0003] In adoptive immunotherapy, natural cells commonly used for adoptive reinfusi...

Images